The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt A Randomized Controlled Trial

RCT (n=197 cirrhosis patients) found rifaximin reduced incidence of post procedure overt hepatic encephalopathy at 168 days vs placebo (34% vs 53%, OR 0.48, 95% CI, 0.27 to 0.87). There was no significant difference in adverse effects or transplant-free survival.

Source:

Annals of Internal Medicine